Search Results

You are looking at 61 - 70 of 1,182 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Heidi Ko, Yaser Baghdadi, Charito Love, and Joseph A. Sparano

for categorical variables. Association Between Clinical Characteristics and Upstaging Frequencies Associations between clinical characteristics and upstaging frequencies were assessed using the Fisher exact test for categorical variables and the

Full access

Benjamin M. Parsons, Dipesh Uprety, Angela L. Smith, Andrew J. Borgert, and Leah L. Dietrich

potential associations between sociodemographic, stage, estrogen receptor (ER)/progesterone receptor (PR) status, and tumor and treatment characteristics using Pearson chi-square or Fisher exact tests. Survival analysis using Kaplan-Meier curves Figure 1

Full access

Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque

years. 4 , 5 Covariates Patient demographic and clinical characteristics were compared and used for model adjustment, including age at index diagnosis, race (white, black, other) type of MBC (de novo vs treated, secondary metastatic disease), HR status

Full access

Ayal A. Aizer, Xiangmei Gu, Ming-Hui Chen, Toni K. Choueiri, Neil E. Martin, Jason A. Efstathiou, Andrew S. Hyatt, Powell L. Graham, Quoc-Dien Trinh, Jim C. Hu, and Paul L. Nguyen

cancer and a short life expectancy in the United States. Subjects/Patients and Methods Patient Characteristics and Study Design A population-based study was conducted of patients with low-risk prostate cancer identified by the SEER

Full access

Randy C. Miles, Christoph I. Lee, Qin Sun, Aasthaa Bansal, Gary H. Lyman, Jennifer M. Specht, Catherine R. Fedorenko, Mikael Anne Greenwood-Hickman, Scott D. Ramsey, and Janie M. Lee

. Clinical data included age at diagnosis, race, diagnosis year, family history of breast cancer, and breast cancer–specific genetic mutation status. Tumor characteristic data included AJCC stage, grade, size, and estrogen receptor (ER), progesterone receptor

Full access

Nina N. Sanford, Todd A. Aguilera, Michael R. Folkert, Chul Ahn, Brandon A. Mahal, Herbert Zeh, Muhammad S. Beg, John Mansour, and David J. Sher

delivery of postoperative chemotherapy include clinical factors, such as patient age, extent of postoperative complications, and presence of lymph node metastases. 10 – 13 In contrast, sociodemographic characteristics influencing receipt of adjuvant

Full access

Toru Okuyama, Koji Sugano, Shinsuke Iida, Takashi Ishida, Shigeru Kusumoto, and Tatsuo Akechi

was taking was investigated by a review of the medical records. Table 1 Patient Demographics and Clinical Characteristics (N=106) Depression: Presence/absence of depression was assessed using the PHQ-9. 23 The PHQ-9 consists of 9

Full access

Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma

). Patient demographics and clinical characteristics are detailed in Table 1 . Of the patients, 98% were women, 78% were white, and 19.5% were black. Median age was 59.4 years (range, 50.7–67.7 years) at initiation of palbociclib treatment. Most patients (n

Full access

Rongbo Lin, Sunzhi Lin, Shuitu Feng, Qingyi Wu, Jianqian Fu, Fang Wang, Hui Li, Xiaofeng Li, Gaowang Zhang, Yongzhi Yao, Min Xin, Tianyang Lai, Xia Lv, Yigui Chen, Shangwang Yang, Yubiao Lin, Lixia Hong, Zhenyu Cai, Jianfeng Wang, Gen Lin, Shaowei Lin, Shen Zhao, Jinfeng Zhu, and Cheng Huang

pain control. Median initial dosages in opioid-tolerant patients were 1 mg (IQR, 0.5–2) and 1 mg (IQR, 0.5–2) in the PCA and non-PCA groups, respectively. Baseline characteristics ( Table 1 ) were well balanced between the 2 groups, with comparable ESAS

Full access

Antonious Hazim, Gordon Mills, Vinay Prasad, Alyson Haslam, and Emerson Y. Chen

involved CAR T-cell therapy. The most common cancer types were leukemia (16%), lung (12%), and breast (10%) ( Table 1 ). Table 1. Characteristics of Dose-Escalation Trials Of the 3,890 patients, 2,506 had both response and dose data, among whom the ORR (CR